Cell adhesion

St. Baldrick's Foundation Allocates $1.1 Million for Fellowships to Empower Emerging Childhood Cancer Researchers

Retrieved on: 
Friday, March 8, 2024

The St. Baldrick's Foundation granted over $1.1 million in Fellow awards to nurture emerging childhood cancer researchers dedicated to overcoming pediatric cancers.

Key Points: 
  • The St. Baldrick's Foundation granted over $1.1 million in Fellow awards to nurture emerging childhood cancer researchers dedicated to overcoming pediatric cancers.
  • The $1.1 million was distributed to seven researchers making strides in discovering new cures for pediatric cancers.
  • The St. Baldrick's Foundation 2024 Fellows are:
    Dr. Vanja Cabric at Memorial Sloan Kettering Cancer Center, New York, NY
    Hepatoblastoma, common in childhood, lacks effective immunotherapy due to limited understanding of pediatric immune response to tumors.
  • Since 2005, St. Baldrick's has granted more than $342 million to support the development of childhood cancer treatments that have the potential to impact every kid diagnosed with cancer.

Bone Solutions Receives 510(k) Clearance for Expanded Indications of Use for Mg OSTEOCRETE in Intervertebral Body Fusion Procedures

Retrieved on: 
Tuesday, February 13, 2024

Bone Solutions Inc. , an orthobiologics technology company located in Colleyville, Texas, announced today 510(k) clearance of Mg OSTEOCRETE from the U.S. Food and Drug Administration (FDA) for use in the intervertebral body disc space, including cervical, thoracic, and lumbar fusion procedures.

Key Points: 
  • Bone Solutions Inc. , an orthobiologics technology company located in Colleyville, Texas, announced today 510(k) clearance of Mg OSTEOCRETE from the U.S. Food and Drug Administration (FDA) for use in the intervertebral body disc space, including cervical, thoracic, and lumbar fusion procedures.
  • This expanded indication allows surgeons and patients to further benefit from the advantages of the Bone Solutions proprietary magnesium-based technology.
  • Mg OSTEOCRETE is a fast-setting bone substitute that remodels into bone over time through creeping substitution.
  • The magnesium component of Mg OSTEOCRETE is the significant differentiator from other bone substitutes on the market.

Frost & Sullivan Co-Published Recombinant Type XVII Collagen Whitepaper with Trautec

Retrieved on: 
Thursday, January 25, 2024

Shanghai, China--(Newsfile Corp. - January 25, 2024) -  Frost & Sullivan and Trautec has conducted extensive investigation across the recombinant type xvii collagen and recombinant type XVII collagen industry chain, and co-published Recombinant Type XVII Collagen Whitepaper, which focuses on the recombinant type xvii collagen and recombinant type XVII collagen industry in China as well as new growth opportunities.

Key Points: 
  • Shanghai, China--(Newsfile Corp. - January 25, 2024) -  Frost & Sullivan and Trautec has conducted extensive investigation across the recombinant type xvii collagen and recombinant type XVII collagen industry chain, and co-published Recombinant Type XVII Collagen Whitepaper, which focuses on the recombinant type xvii collagen and recombinant type XVII collagen industry in China as well as new growth opportunities.
  • (To read the Recombinant Type XVII Collagen Whitepaper, go here: https://hub.frost.com/recombinant-type-xvii-collagen/ .)
  • In the process of skin wound repair, type XVII collagen plays a vital role by influencing the migration, proliferation, and differentiation of stem cells.
  • Recombinant Type XVII Collagen Whitepaper highlights the following:
    Recombinant Type XVII Collagen's Biological Functionality(safety, cell adhesion, anti-wrinkle effect, anti-hair loss effect, etc.

Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

Retrieved on: 
Sunday, January 7, 2024

The preliminary 2023 financial information presented in this press release has not been audited and is subject to change.

Key Points: 
  • The preliminary 2023 financial information presented in this press release has not been audited and is subject to change.
  • The complete Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results are planned for release after market on Tuesday, February 6, 2024.
  • Exelixis expects to substantially complete the restructuring in the first quarter of 2024 and recognize a restructuring charge of approximately $25 million.
  • In 2024, the company expects to designate two new programs to DC status, including a small molecule PLK4 inhibitor and an additional ADC.

Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

Retrieved on: 
Thursday, December 21, 2023

CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival; tusamitamab ravtansine clinical development program will be discontinued

Key Points: 
  • CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival; tusamitamab ravtansine clinical development program will be discontinued
    PARIS, December 21, 2023.
  • Sanofi is discontinuing the global clinical development program of tusamitamab ravtansine.
  • An Independent Data Monitoring Committee (IDMC) found that tusamitamab ravtansine as a monotherapy did not meet its dual primary endpoint of progression-free survival (PFS) compared to docetaxel.
  • “Our team is grateful to the patients, families and healthcare professionals involved in the tusamitamab ravtansine development program.

CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers

Retrieved on: 
Tuesday, October 31, 2023

Visugromab is currently evaluated in a broad Phase 2 program in combination with anti-PD-1 treatment in multiple solid tumor indications.

Key Points: 
  • Visugromab is currently evaluated in a broad Phase 2 program in combination with anti-PD-1 treatment in multiple solid tumor indications.
  • “The new data for the combination of visugromab with bispecific T-cell engagers provide strong scientific support for a synergistic effect in this novel therapeutic setting.
  • When investigating the involvement of additional cell adhesion pathway components downstream of GDF-15, SHP-1 was identified as a central mediator of GDF-15-related inhibition of T cell adhesion.
  • In addition, CatalYm recently announced an exploratory Phase 2 study , GDFather-NEO ( NCT06059547 ), evaluating visugromab in combination with neoadjuvant immunotherapy in first-line muscle-invasive bladder cancer.

Cayman Chemical Introduces a New Tool to Study Protein-Lipid Interactions

Retrieved on: 
Tuesday, September 26, 2023

ANN ARBOR, Mich., Sept. 26, 2023 /PRNewswire-PRWeb/ -- Cayman Chemical, a leading supplier of bioactive lipids, has developed Cayman LipiDOT Strips™ as a research tool for the rapid identification of protein-lipid interactions. This new tool allows researchers to maximize the information gained from early protein-lipid interaction screening campaigns, giving researchers greater insight into protein-lipid interactions while being simple to perform, low cost, and easily completed in a single day.

Key Points: 
  • Cayman LipiDOT Strips™ are a simple tool for the rapid identification of protein-lipid interactions.
  • This new tool allows researchers to maximize the information gained from early protein-lipid interaction screening campaigns, giving researchers greater insight into protein-lipid interactions while being simple to perform, low cost, and easily completed in a single day.
  • Cayman LipiDOT Strips™ - PIPs Plus is the first introduction to Cayman's new product group.
  • Custom biophysical characterization and structural biology solutions are also provided by Cayman to further characterize protein-lipid interactions.

Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial

Retrieved on: 
Tuesday, September 12, 2023

Fort Lee, NJ, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of a Phase 1a dose escalation clinical trial of NXP900, its novel inhibitor of the SRC/YES1 kinase family (“SFK”).

Key Points: 
  • Fort Lee, NJ, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of a Phase 1a dose escalation clinical trial of NXP900, its novel inhibitor of the SRC/YES1 kinase family (“SFK”).
  • The study is designed to evaluate the safety, tolerability and pharmacokinetic properties of NXP900 in patients with advanced solid tumors.
  • SFKs are aberrantly activated in various cancer types and they are central mediators of various oncogenic processes such as proliferation, survival, cell adhesion, invasion, and angiogenesis.
  • NXP900 is a potent and highly selective SFK inhibitor, including low nanomolar IC50 against YES1 and SRC (0.5nM and 2.4nM, respectively) that demonstrated robust single agent anti-cancer activity against several solid tumor types in preclinical models.

LEXEO Therapeutics Announces FDA Clearance of IND for LX2020, an AAV-based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy

Retrieved on: 
Tuesday, August 1, 2023

NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- LEXEO Therapeutics (LEXEO), a clinical-stage gene therapy company advancing adeno-associated virus (AAV)-based gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined sub-group of Alzheimer’s disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for LX2020. LX2020 is an AAVrh10-based gene therapy candidate designed to intravenously deliver a functional PKP2 gene to cardiac muscle for the treatment of Arrhythmogenic Cardiomyopathy (ACM) caused by variants in the PKP2 gene (PKP2-ACM).

Key Points: 
  • LX2020 is an AAVrh10-based gene therapy candidate designed to intravenously deliver a functional PKP2 gene to cardiac muscle for the treatment of Arrhythmogenic Cardiomyopathy (ACM) caused by variants in the PKP2 gene (PKP2-ACM).
  • “This IND clearance marks an important step in advancing a potential one-time treatment for individuals with PKP2-ACM, who are in need of more effective options for this devastating disease.
  • Current clinical management strategies are only marginally effective and primarily focus on symptom management,” said Eric Adler, M.D., Chief Scientific Officer of LEXEO.
  • “LX2020 seeks to address the underlying cause of this disease by delivering a functional PKP2 gene to halt progression and reverse the disease phenotype.

Revolo Biotherapeutics Announces Additional Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis

Retrieved on: 
Tuesday, July 18, 2023

NEW ORLEANS and CAMBRIDGE, United Kingdom, July 18, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced additional data from its proof of concept, 2-week, 3-dose, Phase 2a clinical trial evaluating the efficacy, safety, and tolerability of the company’s immune-resetting drug, ‘1104, in adults with active eosinophilic esophagitis (EoE).

Key Points: 
  • NEW ORLEANS and CAMBRIDGE, United Kingdom, July 18, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced additional data from its proof of concept, 2-week, 3-dose, Phase 2a clinical trial evaluating the efficacy, safety, and tolerability of the company’s immune-resetting drug, ‘1104, in adults with active eosinophilic esophagitis (EoE).
  • The following key observations were made:
    8mg ‘1104 showed a statistically significant ~58% increase in T regulatory cells, that act to suppress inflammatory immune responses, taken from esophageal biopsies
    100% of patients showed an increase in activated CD95+IgD-CD27highCD38high (gated on CD3-CD19+) B regulatory cells that act to suppress inflammatory immune responses.
  • This study supports further clinical evaluation of ‘1104 to treat EoE.”
    The Phase 2a, randomized, double-blind, placebo-controlled trial ( NCT05084963 ) is designed to evaluate the safety and efficacy of ‘1104 in adults with EoE.
  • It is comprised of three arms: ‘1104 at Dose A (n=12), ‘1104 at Dose B (n=12) and the placebo group (n=12) all receiving ‘1104 or placebo once weekly for three weeks (days 0, 7, and 14 of the treatment periods), with a full treatment period of four weeks (30 days).